Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

SomaLogic, Inc. Stock Research

SLGC

2.26USD-0.03(-1.31%)Market Closed
Watchlist

Market Summary

USD2.26-0.03
Market Closed
-1.31%

SLGC Alerts

  • Big jump in Revenue (Y/Y)
  • Losses in recent quarter

SLGC Stock Price

SLGC RSI Chart

SLGC Valuation

Market Cap

430.7M

Price/Earnings (Trailing)

-3.05

Price/Sales (Trailing)

4.25

EV/EBITDA

-0.56

Price/Free Cashflow

-3.1

SLGC Price/Sales (Trailing)

SLGC Profitability

EBT Margin

-164.25%

Return on Equity

-26.04%

Return on Assets

-22.69%

Free Cashflow Yield

-32.25%

SLGC Fundamentals

SLGC Revenue

Revenue (TTM)

101.4M

Revenue Y/Y

44.71%

Revenue Q/Q

0.44%

SLGC Earnings

Earnings (TTM)

-141.2M

Earnings Y/Y

-7.77%

Earnings Q/Q

27.57%

Price Action

52 Week Range

3.79
(Low)(High)

Last 7 days

-0.4%

Last 30 days

13.4%

Last 90 days

9.0%

Trailing 12 Months

-31.6%

SLGC Financial Health

Current Ratio

14.07

SLGC Investor Care

Shares Dilution (1Y)

2.69%

Diluted EPS (TTM)

-0.75

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for SLGC

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-17
Gutierrez Ruben
acquired
-
-
25,000
general counsel
2023-03-17
POST RICHARD A
acquired
-
-
3,430
-
2023-03-17
MEISEL TED D
acquired
-
-
3,430
-
2023-03-17
BARCHI ROBERT
acquired
-
-
3,430
-
2023-03-17
Casdin Eli
acquired
-
-
3,430
-
2023-03-17
Cox Troy
acquired
-
-
28,500
executive chair
2023-03-17
Margulies Anne H.
acquired
-
-
3,430
-
2023-03-17
Blakeman Shaun M.
acquired
-
-
25,000
chief financial officer
2023-03-17
Lillis Charles M.
acquired
-
-
3,430
-
2023-03-17
Graves Amy
acquired
-
-
12,500
chief accounting officer

1–10 of 32

Which funds bought or sold SLGC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-08-24
PERCEPTIVE ADVISORS LLC
unchanged
-
-360,000
3,465,000
0.10%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
5.5
-20,430
440,651
-%
2023-08-21
OSAIC HOLDINGS, INC.
new
-
261
261
-%
2023-08-16
Nuveen Asset Management, LLC
unchanged
-
-99,198
957,802
-%
2023-08-15
ALLIANCEBERNSTEIN L.P.
added
20.71
37,774
441,949
-%
2023-08-15
WELLS FARGO & COMPANY/MN
unchanged
-
-10.00
50.00
-%
2023-08-15
WELLS FARGO & COMPANY/MN
added
82.3
60,395
153,105
-%
2023-08-15
Cowen Investment Management LLC
sold off
-100
-630,426
-
-%
2023-08-15
GOLDMAN SACHS GROUP INC
added
19.79
153,167
1,952,550
-%
2023-08-14
BOOTHBAY FUND MANAGEMENT, LLC
reduced
-4.12
-95,561
631,605
0.01%

1–10 of 47

Latest Funds Activity

Are funds buying SLGC calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SLGC
No. of Funds

Schedule 13G FIlings of SomaLogic

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
gold lawrence marshall
1.9%
3,627,197
SC 13G/A
Feb 03, 2023
blackrock inc.
5.5%
10,268,281
SC 13G
Dec 14, 2022
cmls holdings ii llc
5.8%
11,146,669
SC 13D/A
Feb 11, 2022
gold lawrence marshall
5.04%
9,133,066
SC 13G

Recent SEC filings of SomaLogic

View All Filings
Date Filed Form Type Document
Aug 18, 2023
4
Insider Trading
Aug 18, 2023
4
Insider Trading
Aug 18, 2023
3
Insider Trading
Aug 14, 2023
8-K
Current Report
Aug 14, 2023
10-Q
Quarterly Report
Jun 22, 2023
8-K
Current Report
Jun 15, 2023
3
Insider Trading
Jun 14, 2023
8-K/A
Current Report
Jun 14, 2023
4
Insider Trading
Jun 14, 2023
3
Insider Trading

SomaLogic News

Defense World
Prelude Capital Management LLC Boosts Holdings in SomaLogic ....
Defense World,
13 hours ago
The Motley Fool
Why Shares of SomaLogic Are Up Tuesday.
The Motley Fool,
37 days ago

Returns for SLGC

Cumulative Returns on SLGC

Risks for SLGC

What is the probability of a big loss on SLGC?

86.6%


Probability that SomaLogic stock will be more than 20% underwater in next one year

70.9%


Probability that SomaLogic stock will be more than 30% underwater in next one year.

69.3%


Probability that SomaLogic stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does SLGC drawdown profile look like?

Y-axis is the maximum loss one would have experienced if SomaLogic was unfortunately bought at previous high price.

Drawdowns

Financials for SomaLogic

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q3
Revenue6.7%101,389,00095,065,00097,666,000101,831,00080,110,00085,746,00081,626,00086,855,00081,096,00081,754,66755,889,00056,932,000
Operating Expenses-5.1%247,260,000260,542,667273,427,000-214,142,000184,025,000154,930,000131,508,000106,644,000100,314,66790,245,00080,536,000
  S&GA Expenses-4.5%152,754,000159,993,000156,619,000148,560,000117,956,00095,977,00077,971,00058,401,00046,106,00041,697,33336,882,00033,348,000
  R&D Expenses-9.3%66,890,00073,711,00073,444,00062,047,00058,224,00049,178,00043,496,00039,873,00031,161,00030,094,66730,749,00027,536,000
EBITDA100.0%--150,576,666-105,303,000-130,706,000--------
EBITDA Margin100.0%--1.58-1.08-1.28--------
Interest Expenses-----2,000150,0001,324,00010,072,00011,665,00015,356,00018,338,0006,380,000
Earnings Before Taxes-1.3%-141,880,000-140,090,000-109,874,000-83,789,000-91,644,000-91,552,000-87,509,000-165,676,000----
EBT Margin100.0%--1.64-1.12-1.32--------
Net Income-1.3%-141,167,000-139,380,000-109,157,000-83,213,000-91,690,000-82,042,000-87,547,000-73,154,000-39,218,000-44,920,000-53,015,000-58,801,333
Net Income Margin100.0%--1.47-1.12-0.82-1.14-0.96-1.07-0.84-0.48-0.84-1.03-1.03
Free Cashflow100.0%--143,912,000-105,884,000-96,065,000-74,528,000-45,897,000-43,701,000-26,522,000-3,830,644-1,877,458-37,920,000-37,920,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Assets-4.6%586614647688686713706719277278242
  Current Assets-5.6%5165475826216596906927071.002.00232
    Cash Equivalents-19.1%35543942238041843844046947.0085.00165
  Inventory0.5%15.0015.0014.0018.0021.0014.0011.0011.00--7.00
  Net PPE-5.3%19.0020.0020.0020.0016.0012.0010.006.00--4.00
  Goodwill0%10.0010.0010.0010.00-------
Liabilities-10.6%71.0079.0085.0086.0079.0096.0094.0093.0068.0052.0056.00
  Current Liabilities-19.0%32.0039.0043.0043.0035.0028.0029.0022.000.000.0018.00
Shareholder's Equity-3.8%515535563603607617612626174181186
  Retained Earnings-3.9%-667-642-608-558-525-502-498-475-43.28-26.41-411
  Additional Paid-In Capital0.4%1,1831,1781,1711,1621,1341,1211,1111,10148.0031.00597
Accumulated Depreciation9.0%21.0020.0018.0017.0016.0016.0015.00----
Shares Outstanding0.1%188188188187183182182137115114114
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q3
Cashflow From Operations3.0%-133-137-100-83.88-70.03-42.41-40.38-23.03-9.62-8.96-28.34-37.00
  Share Based Compensation-12.2%37.0042.0044.0043.0039.0034.0028.0026.0018.0017.0015.0013.00
Cashflow From Investing-49.7%66.0013083.00-5.06-95.61-98.97-182-210-150-232-9.5341.00
Cashflow From Financing-82.5%1.004.005.005.0054149849767718836018912.00

SLGC Income Statement

2023-06-30
Condensed Consolidated Statements of Operations and Comprehensive Loss Unaudited - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue    
Collaboration revenue$ 762$ 762$ 1,525$ 1,525
Total revenue20,46814,14440,84737,124
Operating expenses    
Research and development10,81517,63624,88231,436
Selling, general and administrative29,57336,81263,76267,627
Total operating expenses51,56361,525112,135117,792
Loss from operations(31,095)(47,381)(71,288)(80,668)
Other income    
Interest income and other, net5,79883810,7231,047
Change in fair value of warrant liabilities52714,5361,58027,176
Change in fair value of earn-out liability09,0271525,489
Total other income6,32524,40112,31853,712
Net loss before income tax provision(24,770)(22,980)(58,970)(26,956)
Income tax provision(2)(5)(4)(8)
Net loss(24,772)(22,985)(58,974)(26,964)
Other comprehensive income (loss)    
Net unrealized gain (loss) on available-for-sale securities177(209)528(861)
Foreign currency translation gain (loss)4(11)2(14)
Total other comprehensive income (loss)181(220)530(875)
Comprehensive loss$ (24,591)$ (23,205)$ (58,444)$ (27,839)
Net loss per share, basic (in usd per share)$ (0.13)$ (0.13)$ (0.32)$ (0.15)
Net loss per share, diluted (in usd per share)$ (0.13)$ (0.13)$ (0.32)$ (0.15)
Weighted-average shares outstanding used to compute net loss per share, basic (in shares)186,741,112183,143,391186,633,391182,599,949
Weighted-average shares outstanding used to compute net loss per share, diluted (in shares)186,741,112183,143,391186,633,391182,599,949
Assay services revenue    
Revenue    
Revenue$ 16,597$ 10,931$ 35,016$ 29,731
Operating expenses    
Cost of revenue9,6776,57121,35917,951
Product revenue    
Revenue    
Revenue2,9097144,0951,167
Operating expenses    
Cost of revenue1,4985062,132778
Other revenue    
Revenue    
Revenue$ 200$ 1,737$ 211$ 4,701

SLGC Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets Unaudited - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 354,544$ 421,830
Investments119,646117,758
Accounts receivable, net21,75017,006
Inventory15,12313,897
Deferred costs of services4401,337
Prepaid expenses and other current assets4,7609,873
Total current assets516,263581,701
Non-current inventory10,2964,643
Accounts receivable, net of current portion9,0419,284
Property and equipment, net of accumulated depreciation and amortization of $21,390 and $17,899 as of June 30, 2023 and December 31, 2022, respectively18,66819,564
Other long-term assets4,3795,083
Intangible assets16,70016,700
Goodwill10,39910,399
Total assets585,746647,374
Current liabilities  
Accounts payable13,07916,794
Accrued liabilities10,92620,678
Deferred revenue5,0833,383
Other current liabilities2,4132,477
Total current liabilities31,50143,332
Warrant liabilities2,6334,213
Deferred revenue, net of current portion31,20731,732
Other long-term liabilities5,2535,539
Total liabilities70,59484,816
Commitments and contingencies (Note 10)
Stockholders’ equity  
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; no shares issued and outstanding at June 30, 2023 and December 31, 202200
Common stock, $0.0001 par value; 600,000,000 shares authorized; 188,071,445 and 187,647,973 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively1919
Additional paid-in capital1,182,6451,171,122
Accumulated other comprehensive income (loss)17(513)
Accumulated deficit(667,529)(608,070)
Total stockholders’ equity515,152562,558
Total liabilities and stockholders’ equity$ 585,746$ 647,374
Roy Smythe
320
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.